ArticlePloS one2026
Rates of nonproliferative diabetic retinopathy (NPDR) regression among patients with very mild or mild NPDR in an Indian Health Service teleophthalmology program, 2015 - 2020.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) regression is not regularly reported; yet understanding of its prevalence in early-stage DR may impact strategies for eye care management. This study's primary aim was to examine DR regression in patients initially diagnosed with very mild or mild nonproliferative DR (NPDR). A secondary aim was to assess the association between retinopathy regression and diabetes therapy, diabetes duration, and Hemoglobin A1c (HbA1c). This was a retrospective, longitudinal cohort study using medical record data from the United States's Indian Health Service's teleophthalmology program for DR evaluation. Baseline exams occurred in 2015-2017 and follow-up (FU) exams occurred within 3 years of baseline. There were 2,348 patients included in this cohort with very mild NPDR at baseline and 705 patients with mild NPDR. For the whole sample, mean age was 56 ± 12.8 years, 55% were female, diabetes duration was 13.0 ± 9.1 years, and HbA1c was 8.8 ± 2.1%. Proportions for DR regression were 0.47 (CI = .45 - .50) (from very mild NPDR) and 0.36 (CI = 0.33-0.40) (from mild NPDR). Proportions for any DR progression were 0.27 (CI = 0.25-0.29) (from very mild NPDR) and 0.34 (CI = 0.30-0.38) (from mild NPDR). Multivariable analyses showed that lower HbA1c levels were associated with greater odds of diabetic retinopathy regression in patients with either very mild or mild baseline NPDR, whereas insulin use was associated with lower odds of regression. Shorter diabetes duration was associated with greater odds of regression only among patients with very mild NPDR at baseline. DR regression was more frequent than DR progression particularly for patients initially with very mild NPDR. DR reversal was more likely in early-stage DR. Behavioral modifications such as increased physical activity and weight loss that lower HbA1c and subsequent risks for DR progression are important to emphasize in diabetic eye care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.